Conflict of interest
ONCOLOGY, EMD
Yoshihiko Tomita reports support for the present manuscript from Ono Pharmaceutical and Bristol-Myers Squibb; consulting fees from Novartis, Ono Pharmaceutical, Taiho Pharmaceutical and MSD; and payment or honoraria from Astellas Pharma, Novartis, Bristol-Myers Squibb and Ono Pharmaceutical.Ko Kobayashi reports support for the present manuscript from Ono Pharmaceutical and Bristol-Myers Squibb.Go Kimura reports support for the present manuscript from Ono Pharmaceutical and Bristol-Myers Squibb; consulting fees from Eisai; and payment or honoraria from Ono Pharmaceutical, Merck Biopharma, Chugai, Takeda Pharmaceutical, Bristol-Myers Squibb, MSD and Eisai.Mototsugu Oya reports support for the present manuscript from Ono Pharmaceutical and Bristol-Myers Squibb and payment or honoraria from Ono Pharmaceutical and Bristol-Myers Squibb.Hirotsugu Uemura reports support for the present manuscript from Ono Pharmaceutical and Bristol-Myers Squibb; grants from Asahi Kasei Pharma, Janssen Pharmaceutical, Ono Pharmaceutical, Kissei Pharmaceutical, Takeda Pharmaceutical, Sanofi, Daiichi Sankyo, Astellas Pharma and AstraZeneca; consulting fees from Ono Pharmaceutical, Janssen Pharmaceutical and Bayer; and payment or honoraria from Pfizer, Bristol-Myers Squibb, Janssen Pharmaceutical, Merck Biopharma, Bayer, Ono Pharmaceutical, MSD and Sanofi.Hiroyuki Nishiyama reports support for the present manuscript from Ono Pharmaceutical and Bristol-Myers Squibb; grants from Astellas Pharma, Ono Pharmaceutical, Takeda Pharmaceutical and Bayer and payment or honoraria from MSD, Chugai and Astellas Pharma.Matthew D. Galsky reports support for the present manuscript from Ono Pharmaceutical and Bristol-Myers Squibb and grants to the institution from Janssen Oncology, Dendreon, Novartis, Bristol-Myers Squibb, Merck, AstraZeneca and Genentech/Roche; and consulting fees from BioMotiv, Janssen Pharmaceuticals, Dendreon, Merck, GlaxoSmithKline, Eli Lilly and Company, Astellas Pharma, Genentech, Bristol-Myers Squibb, Novartis, Pfizer, EMD Serono, AstraZeneca, Seagen, Incyte Corporation, Aileron Therapeutics, Dracen Pharmaceutical, Inovio Pharmaceuticals, Numab AG, Dragonfly Therapeutics, Basilea Pharmaceutica AG, UroGen Pharma, Infinity Pharmaceuticals and Gilead Sciences.Federico Nasroulah reports support for the present manuscript from Ono Pharmaceutical and Bristol-Myers Squibb and is an employee of and holds stock in Bristol-Myers Squibb.Sandra Collette reports support for the present manuscript from Ono Pharmaceutical and Bristol-Myers Squibb and is an employee of and holds stock or stock options in Bristol-Myers Squibb.Edward Broughton reports support for the present manuscript from Ono Pharmaceutical and Bristol-Myers Squibb; support for attending meetings from Bristol-Myers Squibb; and is an employee of and holds shares in Bristol-Myers Squibb.Keziban Ünsal-Kaçmaz reports support for the present manuscript from Ono Pharmaceutical and Bristol-Myers Squibb and is an employee of and holds stock or stock options in Bristol-Myers Squibb.Yukinori Kamisuki reports support for the present manuscript from Ono Pharmaceutical and Bristol-Myers Squibb and is an employee of Ono Pharmaceutical.Dean F. Bajorin reports support for the present manuscript from Ono Pharmaceutical and Bristol-Myers Squibb; grants from Bristol-Myers Squibb, Merck and Co, Novartis and AstraZeneca; consulting fees from Bristol-Myers Squibb; payment or honoraria from Novartis; and participation on a data safety monitoring board or advisory board for Merck and Co.